Laminin and its related peptides for the treatment of Alzheimer's disease

Akira Monji, Ken Ichiro Tashiro, Ichiro Yoshida, Sadayuki Hashioka, Takahiro Kato, Shigenobu Kanba

Research output: Contribution to journalReview article

Abstract

Alzheimer's disease (AD) is one type of dementing central nervous amyloidosis characterized by two different types of fibrillar deposits, namely senile plaques and neurofibrillary tangles. Amyloid-β-proteins (Aβ) are the major constituents of senile plaques. The aggregation of soluble Aβ into insoluble amyloid fibrils is believed to be an important step in the pathogenesis of AD and the prevention of this process therefore seems to be a promising strategy for the treatment of AD. Laminin is an important extracellular matrix (ECM) protein which has been reported to accumulate in the senile plaques. It supports such biological activities as cell adhesion, cell proliferation, neurite outgrowth. Recent reports have revealed that laminin inhibits both Aβ fibril formation and Aβ neurotoxicity in vitro. Laminin-related peptides, which have almost the same biological activities as laminin, have also recently been reported to inhibit Aβ fibril formation and/or Aβ neurotoxicity. Finally, Laminin can induce a complete disaggregation of Aβ amyloid fibrils by disassembly into protofibrils and subsequently into an amorphous aggregate. These results thus suggested that laminin or its related peptides may be useful as an effective therapeutic agent for the treatment of AD.

Original languageEnglish
Pages (from-to)243-247
Number of pages5
JournalCurrent Medicinal Chemistry - Central Nervous System Agents
Volume5
Issue number4
DOIs
Publication statusPublished - Dec 1 2005

Fingerprint

Laminin
Alzheimer Disease
Peptides
Amyloid Plaques
Amyloid
Serum Amyloid A Protein
Neurofibrillary Tangles
Extracellular Matrix Proteins
Amyloidosis
Cell Adhesion
Cell Proliferation

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Neuropsychology and Physiological Psychology
  • Molecular Medicine

Cite this

Laminin and its related peptides for the treatment of Alzheimer's disease. / Monji, Akira; Tashiro, Ken Ichiro; Yoshida, Ichiro; Hashioka, Sadayuki; Kato, Takahiro; Kanba, Shigenobu.

In: Current Medicinal Chemistry - Central Nervous System Agents, Vol. 5, No. 4, 01.12.2005, p. 243-247.

Research output: Contribution to journalReview article

Monji, Akira ; Tashiro, Ken Ichiro ; Yoshida, Ichiro ; Hashioka, Sadayuki ; Kato, Takahiro ; Kanba, Shigenobu. / Laminin and its related peptides for the treatment of Alzheimer's disease. In: Current Medicinal Chemistry - Central Nervous System Agents. 2005 ; Vol. 5, No. 4. pp. 243-247.
@article{95a390f6f63742edad0272fa3bb4098a,
title = "Laminin and its related peptides for the treatment of Alzheimer's disease",
abstract = "Alzheimer's disease (AD) is one type of dementing central nervous amyloidosis characterized by two different types of fibrillar deposits, namely senile plaques and neurofibrillary tangles. Amyloid-β-proteins (Aβ) are the major constituents of senile plaques. The aggregation of soluble Aβ into insoluble amyloid fibrils is believed to be an important step in the pathogenesis of AD and the prevention of this process therefore seems to be a promising strategy for the treatment of AD. Laminin is an important extracellular matrix (ECM) protein which has been reported to accumulate in the senile plaques. It supports such biological activities as cell adhesion, cell proliferation, neurite outgrowth. Recent reports have revealed that laminin inhibits both Aβ fibril formation and Aβ neurotoxicity in vitro. Laminin-related peptides, which have almost the same biological activities as laminin, have also recently been reported to inhibit Aβ fibril formation and/or Aβ neurotoxicity. Finally, Laminin can induce a complete disaggregation of Aβ amyloid fibrils by disassembly into protofibrils and subsequently into an amorphous aggregate. These results thus suggested that laminin or its related peptides may be useful as an effective therapeutic agent for the treatment of AD.",
author = "Akira Monji and Tashiro, {Ken Ichiro} and Ichiro Yoshida and Sadayuki Hashioka and Takahiro Kato and Shigenobu Kanba",
year = "2005",
month = "12",
day = "1",
doi = "10.2174/156801505774913017",
language = "English",
volume = "5",
pages = "243--247",
journal = "Central Nervous System Agents in Medicinal Chemistry",
issn = "1871-5249",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Laminin and its related peptides for the treatment of Alzheimer's disease

AU - Monji, Akira

AU - Tashiro, Ken Ichiro

AU - Yoshida, Ichiro

AU - Hashioka, Sadayuki

AU - Kato, Takahiro

AU - Kanba, Shigenobu

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Alzheimer's disease (AD) is one type of dementing central nervous amyloidosis characterized by two different types of fibrillar deposits, namely senile plaques and neurofibrillary tangles. Amyloid-β-proteins (Aβ) are the major constituents of senile plaques. The aggregation of soluble Aβ into insoluble amyloid fibrils is believed to be an important step in the pathogenesis of AD and the prevention of this process therefore seems to be a promising strategy for the treatment of AD. Laminin is an important extracellular matrix (ECM) protein which has been reported to accumulate in the senile plaques. It supports such biological activities as cell adhesion, cell proliferation, neurite outgrowth. Recent reports have revealed that laminin inhibits both Aβ fibril formation and Aβ neurotoxicity in vitro. Laminin-related peptides, which have almost the same biological activities as laminin, have also recently been reported to inhibit Aβ fibril formation and/or Aβ neurotoxicity. Finally, Laminin can induce a complete disaggregation of Aβ amyloid fibrils by disassembly into protofibrils and subsequently into an amorphous aggregate. These results thus suggested that laminin or its related peptides may be useful as an effective therapeutic agent for the treatment of AD.

AB - Alzheimer's disease (AD) is one type of dementing central nervous amyloidosis characterized by two different types of fibrillar deposits, namely senile plaques and neurofibrillary tangles. Amyloid-β-proteins (Aβ) are the major constituents of senile plaques. The aggregation of soluble Aβ into insoluble amyloid fibrils is believed to be an important step in the pathogenesis of AD and the prevention of this process therefore seems to be a promising strategy for the treatment of AD. Laminin is an important extracellular matrix (ECM) protein which has been reported to accumulate in the senile plaques. It supports such biological activities as cell adhesion, cell proliferation, neurite outgrowth. Recent reports have revealed that laminin inhibits both Aβ fibril formation and Aβ neurotoxicity in vitro. Laminin-related peptides, which have almost the same biological activities as laminin, have also recently been reported to inhibit Aβ fibril formation and/or Aβ neurotoxicity. Finally, Laminin can induce a complete disaggregation of Aβ amyloid fibrils by disassembly into protofibrils and subsequently into an amorphous aggregate. These results thus suggested that laminin or its related peptides may be useful as an effective therapeutic agent for the treatment of AD.

UR - http://www.scopus.com/inward/record.url?scp=28244445599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28244445599&partnerID=8YFLogxK

U2 - 10.2174/156801505774913017

DO - 10.2174/156801505774913017

M3 - Review article

VL - 5

SP - 243

EP - 247

JO - Central Nervous System Agents in Medicinal Chemistry

JF - Central Nervous System Agents in Medicinal Chemistry

SN - 1871-5249

IS - 4

ER -